Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the FoF Domestic median (128 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 13 Feb 2026 – 20 Aug 2026, limited by Groww Nifty PSE ETF FOF. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Groww Nifty PSE ETF FOF | Nifty 500 |
|---|---|---|
| 13 Feb 2026 | ₹100.00 | ₹100.00 |
| 01 Mar 2026 | ₹100.83 | ₹99.37 |
| 16 Mar 2026 | ₹97.25 | ₹92.22 |
| 01 Apr 2026 | ₹95.71 | ₹89.80 |
| 17 Apr 2026 | ₹104.17 | ₹98.10 |
| 02 May 2026 | ₹103.93 | ₹97.30 |
| 18 May 2026 | ₹101.48 | ₹96.34 |
| 03 Jun 2026 | ₹99.51 | ₹96.31 |
| 18 Jun 2026 | ₹100.14 | ₹99.54 |
| 04 Jul 2026 | ₹97.96 | ₹99.95 |
| 20 Jul 2026 | ₹97.82 | ₹100.11 |
| 04 Aug 2026 | ₹97.48 | ₹101.62 |
| 20 Aug 2026 | ₹95.32 | ₹100.86 |
| Metric | Groww · Regular · IDCW NAV ₹9.39 Very High risk Unrated | Category median FoF Domestic · 128 funds |
|---|---|---|
| — | +5.71% | |
| — | +10.60% | |
| — | +7.04% | |
| — | +8.12% | |
| -4.68% | +8.44% | |
| -16.32% | — | |
| — | +9.37% | |
| — | +8.64% | |
| — | +8.30% | |
| Risk | ||
| 16.75% | 13.12% | |
| — | 0.40 | |
| — | 0.57 | |
| -9.99% | -18.33% | |
| Nifty 500 | — | |
| — | +0.09% | |
| — | 0.95 | |
| — | 92.9% | |
| — | 81.4% | |
| 0.52% | 0.58% | |
| ₹11.95Cr | ₹372.62Cr | |
| None | — | |
| None | — | |
| ₹500 | — | |
| ₹500 | — | |
| 2% | 13% | |
| Nikhil Satam | — | |
| 13 Feb 2026 | — | |
| — | — | |
| — | — | |
| 0.1% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.